Daiwa Securities Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Daiwa Securities Group’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-266	Closed	-$32K	–	1269
2020 Q2	$32K	Hold	266	–	–	﹤0.01%	997
2020 Q1	$13K	Hold	266	–	–	﹤0.01%	1044
2019 Q4	$12K	Sell	266 -34	-11%	-$1.5K	﹤0.01%	1050
2019 Q3	$7K	Buy	300 +33	+12%	+$978	﹤0.01%	1060
2019 Q2	$8K	Hold	267	–	–	﹤0.01%	1073
2019 Q1	$6K	Buy	267 +142	+114%	+$3.05K	﹤0.01%	1077
2018 Q4	$2K	Hold	125	–	–	﹤0.01%	1120
2018 Q3	$2K	Hold	125	–	–	﹤0.01%	1138
2018 Q2	$1K	Hold	125	–	–	﹤0.01%	1180
2018 Q1	$1K	Buy	+125	New	+$893	﹤0.01%	1166

Daiwa Securities Group's RARX Position: Q3 2020 in Review

Daiwa Securities Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q3 2020, closing a stake of 266 shares — an estimated $32K sold.

Daiwa Securities Group first reported a position in RARX in Q1 2018 and held it in 10 quarters. The position peaked at $32K in Q2 2020. 0 funds tracked by Wall St. Rank hold RARX as of Q3 2020.

Daiwa Securities Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
Daiwa Securities Group sold 266 Ra Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $32K.
Daiwa Securities Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 10 quarters.
Daiwa Securities Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $32K in Q2 2020.
0 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Daiwa Securities Group's 13F filing for Q3 2020, filed 2 Nov 2020.